Aethlon director forfeits 178 shares for taxes
Aethlon Medical director Nicolas Gikakis reported a tax-related share forfeiture.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Aethlon Medical director Nicolas Gikakis reported a tax-related share forfeiture. On the conversion of 268 vested restricted stock units into common stock, he forfeited 178 shares to cover tax withholdings, using a market price of $2.19 per share. Following the disposition, he holds 1,464 common shares directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 178 | $2.19 | $389.82 |
Footnotes (1)
- F1. The Reporting Person forfeited 178 shares of common stock upon conversion of an aggregate 268 vested and outstanding restricted stock units into shares of common stock to cover tax withholdings, using the market price of the issuer's common stock at the time of forfeiture. These restricted stock units were part of the grant reported in Table I of the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on April 25, 2025.
Key Figures
Key Terms
restricted stock units financial
tax withholdings financial
forfeited financial
Form 4 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aethlon Medical (AEMD) director Nicolas Gikakis report in this Form 4?
What equity award triggered the tax-withholding disposition for Aethlon Medical director Gikakis?
AI-generated analysis. How Rhea-AI works. Not financial advice.